If you have walked into a smoke shop or gas station recently, you have probably seen products labeled “7-OH” next to kratom — tablets, gummies, shots and dissolvable strips. They are often marketed as kratom. They are not the same thing, and the difference now matters for both safety and the law.
Key takeaways
- 7-hydroxymitragynine (7-OH) occurs in kratom leaf only in trace amounts.
- Many 7-OH products are concentrated or semi-synthetic, with far more 7-OH than natural leaf.
- 7-OH is much more potent at opioid receptors than mitragynine, kratom’s main alkaloid.
- Federal regulators are targeting concentrated and synthetic 7-OH, not leaf kratom below a set threshold.
- Many states now ban or cap 7-OH even where kratom leaf is legal.
What is 7-OH?
7-hydroxymitragynine is one of the many alkaloids in Mitragyna speciosa. In the dried leaf, it is present only in tiny amounts. The body also produces some 7-OH as it breaks down mitragynine, the leaf’s most abundant alkaloid.
What makes 7-OH significant is its strength. It binds to the brain’s mu-opioid receptors much more strongly than mitragynine does. The FDA has described 7-OH as having opioid-like effects and potential for addiction. For more on how the compounds compare, see Kratom Alkaloids Explained.
How 7-OH products are made
Because natural leaf contains so little 7-OH, products marketed around it are typically made by chemically converting mitragynine into 7-OH, or by heavily concentrating extracts. The result is a product with many times the 7-OH content of natural leaf. DEA laboratory testing has found that commercial 7-OH products often contain much higher levels than botanical kratom.
That is the central point: a 7-OH tablet is a manufactured product, not simply a convenient form of the plant.
Why regulators are focused on 7-OH
Federal and state officials have become increasingly concerned about these products for several reasons: they are widely sold in convenience stores and online, they come in forms like fruit-flavored gummies that can appeal to young people, their effects are less predictable, and their potency at opioid receptors is high.
The federal timeline so far:
- July 2025: The FDA recommended scheduling 7-OH and issued warning letters to companies marketing 7-OH products.
- July 2026: The DEA announced its intent to temporarily place 7-OH above a set concentration, plus three related synthetic compounds, in Schedule I.
- August 26, 2026: Three synthetic compounds — mitragynine pseudoindoxyl, MGM-15 and MGM-16 — were temporarily placed in Schedule I.
- October 2026: The DEA reissued its 7-OH notice with a revised threshold. The 7-OH order is still pending as of this writing.
The DEA, FDA and HHS have each said that this action is not intended to cover botanical kratom leaf with naturally occurring 7-OH below the threshold. The American Kratom Association, the main consumer advocacy group for kratom, has supported restricting concentrated 7-OH on the grounds that it is falsely marketed as kratom.
State action on 7-OH
States have moved faster than the federal government. Several have banned 7-OH or limited the amount a product can contain while leaving leaf kratom legal. Rhode Island’s 2026 law, for example, legalized regulated kratom sales but set strict caps on 7-OH per gram and per serving. Florida, Colorado, Mississippi and Ohio have also acted against concentrated or synthetic 7-OH. See our state-by-state legal guide for the current picture.
How to tell what you are looking at
- Read the label. If “7-OH,” “7-hydroxymitragynine” or a milligram amount of 7-OH is the headline, it is a 7-OH product, whatever else the packaging says.
- Look at the form. Tablets, gummies, strips and small high-strength shots are more likely to be concentrated products.
- Ask for a lab report. A reputable product should have third-party testing showing its alkaloid content. Our guide on reading a kratom label and lab report explains what to look for.
Frequently asked questions
Is 7-OH banned?
Federally, a final order on 7-OH was still pending as of October 2026, though three related synthetic compounds are now temporarily Schedule I. Many states already ban or restrict 7-OH.
Is 7-OH stronger than kratom?
Yes. 7-OH is substantially more potent at opioid receptors than mitragynine, and concentrated 7-OH products contain much more of it than natural leaf.
Does the DEA action ban kratom leaf?
No. Regulators have said the action targets concentrated and synthetic products, not botanical kratom with naturally occurring 7-OH below the threshold.
Can 7-OH cause dependence?
Yes. Health officials report dependence and withdrawal symptoms such as restlessness, body aches, fatigue and sweating. If you or someone you know is struggling, SAMHSA’s National Helpline (1-800-662-4357) is free, confidential and available 24/7.
Sources
- FDA: FDA Takes Steps to Restrict 7-OH Opioid Products (July 2025)
- FDA: Hiding in Plain Sight: 7-OH Products
- FDA: 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data
- DEA: DEA to Temporarily Schedule 7-OH and Related Substances (July 1, 2026)
- HHS: HHS, FDA Commend DEA Action Against Enhanced 7-OH Products
- Congressional Research Service: Temporary Control of 7-OH and Other Kratom-Related Substances
- R.I. Gen. Laws § 21-28.12-3: Kratom and Kratom Product Limitations
Kratom Universe publishes independent educational information. Nothing on this site is medical or legal advice. Kratom is not approved by the FDA to diagnose, treat, cure or prevent any disease. Talk with a healthcare provider before using kratom, and check your state and local laws. If you or someone you know is struggling with substance use, call SAMHSA’s free, confidential National Helpline at 1-800-662-4357.
